Economic issues in access to medications: schizophrenia treatment in England.

[1]  A. Basu.  Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues , 2004, Schizophrenia Research.

[2]  Trevor A Sheldon,et al.  What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews , 2004, BMJ : British Medical Journal.

[3]  N. Freemantle.  Is NICE delivering the goods? , 2004, British medical journal.

[4]  Nick Freemantle,et al.  Challenges for the National Institute for Clinical Excellence , 2004, BMJ : British Medical Journal.

[5]  Helen Lapsley,et al.  Utilising survey data to inform public policy: Comparison of the cost-effectiveness of treatment of ten mental disorders , 2004, British Journal of Psychiatry.

[6]  David Parkin,et al.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.

[7]  T. Walley,et al.  Neuropsychotherapeutics in the UK , 2004, CNS Drugs.

[8]  R. Brook.  Medicines regulation in the UK: The case for reform , 2004 .

[9]  B. Bradbury,et al.  Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. , 2003, British journal of clinical pharmacology.

[10]  P. Lelliott,et al.  Patterns of Antipsychotic and Anticholinergic Prescribing for Hospital Inpatients , 2003, Journal of psychopharmacology.

[11]  D. Melzer,et al.  Social position and the common mental disorders with disability , 2003, Social Psychiatry and Psychiatric Epidemiology.

[12]  J. Alonso,et al.  The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment , 2003, Acta psychiatrica Scandinavica.

[13]  S. Lewis,et al.  Postcode prescribing for schizophrenia , 2003, Schizophrenia Research.

[14]  I. Glick,et al.  A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.

[15]  A. David,et al.  Psychiatrists' attitudes to maintenance medication for patients with schizophrenia , 2002, Psychological Medicine.

[16]  N. Wolff.  Risk, Response, and Mental Health Policy: Learning from the Experience of the United Kingdom , 2002, Journal of health politics, policy and law.

[17]  M. Frischer,et al.  Variations in prescribing atypical antipsychotic drugs in primary care: cross‐sectional study , 2002, Pharmacoepidemiology and drug safety.

[18]  M. Knapp,et al.  Depot antipsychotic preparations in schizophrenia: the state of the economic evidence , 2002, International clinical psychopharmacology.

[19]  A. David,et al.  Systematic meta-review of depot antipsychotic drugs for people with schizophrenia , 2001, British Journal of Psychiatry.

[20]  R. Coulson,et al.  Revitalizing the General Practice Research Database: plans, challenges, and opportunities , 2001, Pharmacoepidemiology and drug safety.

[21]  C. Adams,et al.  “Nobody ever expects the Spanish Inquisition” (Python, 1991) , 2001 .

[22]  G. Hogman.  The National Schizophrenia Fellowship on treatment guidelines , 2001 .

[23]  P. Bebbington.  Choosing antipsychotic drugs in schizophrenia: a personal view , 2001 .

[24]  D. Healy.  Evidence biased psychiatry , 2001 .

[25]  A. Mortimer.  First-line atypical antipsychotics for schizophrenia are appropriate - with psychosocial interventions , 2001 .

[26]  P Bebbington,et al.  Unequal access and unmet need: neurotic disorders and the use of primary care services , 2000, Psychological Medicine.

[27]  S. Lewis,et al.  Postcode prescribing in psychiatry , 2000 .

[28]  K. Concannon,et al.  Should pharmaceutical prices be regulated? , 2000, Hospitals & Health Networks.

[29]  David Goldberg,et al.  Expenditure on mental health care by English health authorities: a potential cause of inequity. , 2000, The British journal of psychiatry : the journal of mental science.

[30]  M. Hazelton,et al.  Architecture signifying social control: the restoration of asylumdom in mental health care? , 2000, The Australian and New Zealand journal of mental health nursing.

[31]  T. Kendrick,et al.  Are specialist mental health services being targeted on the most needy patients? The effects of setting up special services in general practice. , 2000, The British journal of general practice : the journal of the Royal College of General Practitioners.

[32]  M. Marshall.  Modernising mental health services , 1999, BMJ.

[33]  P. Taylor,et al.  Homicides by people with mental illness: myth and reality , 1999, British Journal of Psychiatry.

[34]  R. Conley,et al.  Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[35]  P. Hardy,et al.  One day survey by the Mental Health Act Commission of acute adult psychiatric inpatient wards in England and Wales , 1998, BMJ.

[36]  M. Knapp.  Costs of schizophrenia , 1997, British Journal of Psychiatry.

[37]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[38]  K. Newton,et al.  Antipsychotic prescribing in light of the consensus statement of the College , 1997 .

[39]  S. Kavanagh.  Purchasers, providers and managed care: developments in the mental health market place , 1997 .

[40]  B. Sibbald,et al.  Evaluating models of working at the interface between mental health services and primary care , 1997, British Journal of Psychiatry.

[41]  H. Goldman,et al.  Effects of mental health services reform on clinical practice in the United Kingdom. , 1996, Psychiatric services.

[42]  S. Dencker,et al.  Optimising the Use of Depot Antipsychotics , 1996 .

[43]  P. Lelliott,et al.  Fundholding and the care of the mentally ill , 1996 .

[44]  F. Holloway.  Community psychiatric care: from libertarianism to coercion. Moral panic and mental health policy in Britain. , 1996, Health care analysis : HCA : journal of health philosophy and policy.

[45]  G. Fenton,et al.  Influences on psychotropic drug prescription in a psychiatric service , 1996 .

[46]  J. Tingle.  By accident or design , 1996 .

[47]  A. Tylee,et al.  The Treatment of Depression: Prescribing Patterns of Antidepressants in Primary Care in the UK , 1996, British Journal of Psychiatry.

[48]  H. Goldman,et al.  Effect of recent health and social service policy reforms on Britain's mental health system , 1995, BMJ.

[49]  M. Knapp,et al.  Market Rationales, Rationing, And Rationality: Mental Health Care Reform In The United Kingdom , 1995 .

[50]  M. Knapp,et al.  The global costs of schizophrenia. , 2004, Schizophrenia bulletin.

[51]  R. Whitaker.  The case against antipsychotic drugs: a 50-year record of doing more harm than good. , 2004, Medical hypotheses.

[52]  Silvio Garattini,et al.  Technology Appraisal Programme of the National Institute for Clinical Excellence , 2003 .

[53]  David Taylor,et al.  Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. , 2003, The Journal of clinical psychiatry.

[54]  J. Silcock,et al.  Trends in psychotropic drug use in older patients in general hospitals , 2003 .

[55]  R. Kerwin,et al.  A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. , 2000 .

[56]  P. Young,et al.  The use of atypical antipsychotics in the management of schizophrenia. , 1999, British journal of clinical pharmacology.

[57]  P. Lelliott,et al.  London's Mental Health. , 1997 .